Advanced in Langerhans Cell Histiocytosis

Dr. Barbara A. Degar

Pediatric Hematology Oncology
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
Advanced in Langerhans Cell Histiocytosis
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Barbara Degar is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Degar is rated as an Advanced provider by MediFind in the treatment of Langerhans Cell Histiocytosis. Her top areas of expertise are Hemophagocytic Lymphohistiocytosis, Non-Langerhans-Cell Histiocytosis, Reticulohistiocytoma, and Histiocytosis.

Her clinical research consists of co-authoring 37 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 8 articles and participated in 1 clinical trial in the study of Langerhans Cell Histiocytosis.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in MA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215

Additional Areas of Focus

Dr. Degar has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug
Study Drug: Clofarabine
Study Phase: Phase 2
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug, Combination product, Biological
Study Drugs: Methotrexate, Hydrocortisone, Azacitidine, Decitabine, Cytarabine, Daunorubicin, Etoposide, Idarubicin, Fludarabine, Mitoxantrone, Erwinia Asparaginase, Sorafenib, Granulocyte Colony-Stimulating Factor, Dexrazoxane
Study Phase: Phase 2
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2024
Intervention Type: Other, Drug
Study Drugs: Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Mitoxantrone, Tretinoin
Study Phase: Phase 3
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Emapalumab
Study Phase: Phase 3
A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia
AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: August 10, 2021
Intervention Type: Drug, Device
Study Phase: Phase 3
View 7 Less Clinical Trials

37 Total Publications

Identifying Targeted Therapies for CBFA2T3::GLIS2 Acute Myeloid Leukemia.
Identifying Targeted Therapies for CBFA2T3::GLIS2 Acute Myeloid Leukemia.
Journal: Research square
Published: June 05, 2025
Similar Doctors
Advanced in Langerhans Cell Histiocytosis
Dr. Katherine A. Janeway
Pediatric Hematology Oncology
Advanced in Langerhans Cell Histiocytosis
Dr. Katherine A. Janeway
Pediatric Hematology Oncology
Dana Farber Cancer Institute, 44 Binney Street, 
Boston, MA 
 (0.1 miles away)
617-632-4994
Languages Spoken:
English
See accepted insurances

Katherine Janeway is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Janeway is rated as a Distinguished provider by MediFind in the treatment of Langerhans Cell Histiocytosis. Her top areas of expertise are Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Neuroblastoma, and Bone Marrow Aspiration.

Experienced in Langerhans Cell Histiocytosis
Dr. Mark W. Kieran
Pediatric Hematology Oncology
Experienced in Langerhans Cell Histiocytosis
Dr. Mark W. Kieran
Pediatric Hematology Oncology
44 Binney St, Room Sw331, 
Boston, MA 
 (0.1 miles away)
617-632-4907
Languages Spoken:
English
See accepted insurances

Mark Kieran is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Kieran is rated as a Distinguished provider by MediFind in the treatment of Langerhans Cell Histiocytosis. His top areas of expertise are Glioma, Brain Stem Cancer, Diffuse Midline Glioma H3 K27M-Mutant, and Medulloblastoma.

Experienced in Langerhans Cell Histiocytosis
Dr. Karen L. Bride
Pediatric Hematology Oncology
Experienced in Langerhans Cell Histiocytosis
Dr. Karen L. Bride
Pediatric Hematology Oncology
300 Longwood Ave, 
Boston, MA 
 (0.1 miles away)
617-355-6000
Languages Spoken:
English
See accepted insurances

Karen Bride is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Bride is rated as an Advanced provider by MediFind in the treatment of Langerhans Cell Histiocytosis. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Renal Vein Thrombosis, Graft Versus Host Disease (GvHD), and Hepatic Venoocclusive Disease with Immunodeficiency.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Degar's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile